Appeal against NICE’s recommendation that efgartigimod should not be recommended for NHS use

20 February 2025

We have supported an appeal by the charity myaware and clinical experts to the National Institute for Health and Care Excellence (NICE) against its recent decision to not recommend NHS use of efgartigimod (Vyvgart) in England.

Last month, NICE announced that efgartigimod should not be recommend for use on the NHS in England. NICE recognised that efgartigimod can be beneficial for people with myasthenia gravis but decided there were too many gaps or uncertainties in the evidence to show that the treatment was good value for money.

Since the decision was announced, we have worked with the charity myaware and clinical experts in myasthenia gravis to see how we can continue campaigning for access to efgartigimod. As a result, we have supported an appeal to NICE against its decision.

The company who developed efgartigimod, Argenx, have also submitted their own appeal to NICE.

Next steps

A panel will meet on 6 May 2025 to hear from representatives who submitted the appeals. Representatives will cover the reason for the appeal and provide evidence to showcase that they believe the decision made by NICE was incorrect.

People affected by myasthenia gravis can request to attend the meeting as an observer. This means you will only be able to view the meeting and would not be able to ask questions or present your views on the appeal. If you would like to attend the meeting, please register your interest on the NICE website.